News

Together for Ukraine

Together for Ukraine

07 April 2022
Neupharma took part to the charity collection of pharmaceutical products in order to help Cystic Fibrosis patients in war-affected areas
Happy Birthday Neupharma!

Happy Birthday Neupharma!

29 March 2022
Neupharma celebrates its 10th corporate anniversary with a new cover image
DKD Approval for Rare Disease

DKD Approval for Rare Disease

17 March 2022
DKD obtained approval as Food for Special Medical Purposes for Osteogenesis Imperfecta, Ehlers-Danlos Syndrome, Deficiency Rickets

Merry Christmas 2021!!

21 December 2021
Neupharma Team wishes our website users merry Christmas and a happy new year 2022
Neupharma honoured by Le Fonti Awards 2021

Neupharma honoured by Le Fonti Awards 2021

26 November 2021
Neupharma and Davide Fiumi (CEO) honoured for "Corporate Social Responsibility in Healthcare"
Neupharma and #MiFidoDiTe (“I trust you”)

Neupharma and #MiFidoDiTe (“I trust you”)

13 May 2021
Neupharma Srl will sponsor a summer leg of the “MiFidoDiTe” charity project during the Italian Open Water Tour 2021
Inhaled teicoplanin completed phase 1 clinical trial in cystic fibrosis

Inhaled teicoplanin completed phase 1 clinical trial in cystic fibrosis

18 March 2021
Neupharma announces the positive conclusion of the phase 1 study, conducted at the “Azienda Ospedaliera Universitaria Integrata” of Verona, with the formulation of inhaled teicoplanin in CF patients.
Neupharma is included among the 400 companies deserving the

Neupharma is included among the 400 companies deserving the "CHAMPION OF GROWTH" Certification 2016/2019

12 October 2020
The German Quality and Finance Institute published the results of the research entitled "Champions of Growth": the aim was rewarding the 400 companies whose turnover increased most in the three-year period 2016-2019.
The Food and Drug Administration granted Teicoplanin the PEDIATRIC Orphan Drug Designation

The Food and Drug Administration granted Teicoplanin the PEDIATRIC Orphan Drug Designation

28 September 2020
The Food and Drug Administration has granted the Pediatric Orphan Drug Designation to the inhaled formulation of Teicoplanin for patients with Cystic Fibrosis.